At HKEX's 2026 Future Tech Summit, managing director and co-head of IPO review
Liu Ying said 90 biotech companies have listed in Hong Kong under Chapter 18A
since its 2018 introduction, raising HKD142.9 billion; 17 listed in 2025 and a
further six in Jan–May 2026. She said Chapter 18C listings for specialised tech
firms have accelerated — three in 2024, five in 2025 and ten in Jan–May 2026 —
with the cohort concentrated in AI, robotics and autonomous-driving companies.